GE Healthcare Ltd. et al. vs. The Johns Hopkins University et al.

Explore the PTAB proceeding IPR2026-00069 filed by GE Healthcare Ltd. et al. on 2025-10-21. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

IPR2026-00069

Filing Date

2025-10-21

Accorded Filing Date

2025-10-21

Institution Decision Date

2026-03-23

Last Modified Date

2026-10-14

Proceeding Type

IPR

Termination Date

2026-10-14

Trial Status

Terminated-Settled

Parties & Counsel

Petitioner

GE Healthcare Ltd. et al.

Represented By

Kushan, Jeffreyet al

Patent Owner / Respondent

The Johns Hopkins University et al.

Represented By

Ellison, Eldoraet al

Tribunal & Venue

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 1600 - Biotechnology & Organic Chemistry

Patent Information

1 Patent Involved

Respondent Application Number 18354282

Respondent Patent Number 11938201

External Links

Espacenet

Google Patents

Respondent Inventor Xing Yang et al

Respondent Tech Center TC 1600 - Biotechnology & Organic Chemistry

Address and Attorney/Agent Information

33 Registered Practitioners

Power of Attorney & Correspondence

Firm / Entity Name The Johns Hopkins University - c/o Casimir Jones

Customer Number 101943

Address 2275 Deming Way, Suite 310, Middleton, WI, 53562, UNITED STATES

Attorney / Agent Information

Reg #	Name	Phone
38978	Lisa Mueller	312-222-0800
42363	Mary Ann Brow	608-662-1277
42395	David Casimir	608-662-1277
44174	John Jones	608-662-1277
45439	Jason Bond	608-662-1277
47371	Rick Abegglen	608-237-7288
47391	Tanya Arenson	608-662-1277
50210	Thomas Haas	202-659-6659
52926	Tristan Fuierer	608-662-1277
52933	Guido Galvez	410-502-9593
55210	Robert Goetz	608-662-1277
58126	Jeffrey Childers	919-724-8699
59520	Linda Hutchison	410-978-7287
59850	Tyler Sisk	608-662-1277
63215	Louisa Salomon	571-271-7116
63532	Laura Mitchell	410-516-4969
63749	Qi Zhuo	973-245-7747
65033	Kirk Hogan	608-662-1277
65455	Anne Reynolds	608-662-1277
65746	Alevtina Zhelonkina	410-516-7789
65881	Andrew Wichmann	202-787-5532
65903	David Staple	608-662-1277
67792	Peter Schlueter	608-257-3501
71476	Thomas Isenbarger	608-662-1277
71554	Peter Sheppard	443-963-2909
73951	Brian Bradley	608-662-1277
74648	Sempian Sooriakumar	585-469-5508
77414	Rikki Hullinger	508-523-6096
78227	Kelly Barton	608-662-1277
78563	Vincent Carbone	410-308-8897
78578	Anthony Sedivy	440-590-0457
80602	Thomas Lyneis	414-287-9646
82885	Bradley Loren	312-775-8009

Proceeding Documents

144

Termination Decision: TEMINATION Due to Settlement After Institution of Trial TERMINATE

2026-10-14 FILING PARTY: BOARD

Download

Joint Motion to Keep Business Confidential and Separate MOTION

2026-10-01 FILING PARTY: PETITIONER

Download

Joint Motion to Terminate MOTION

2026-10-01 FILING PARTY: PETITIONER

Download

ORDER Setting Oral Argument 37 C.F.R. § 42.70 ORDER

2026-09-17 FILING PARTY: BOARD

Download

Petitioner's Request for Oral Argument OTHER

2026-09-02 FILING PARTY: PETITIONER

Download

GE Healthcare Ltd. et al. vs. The Johns Hopkins University et al.

Proceeding Overview

Parties & Counsel

Petitioner

GE Healthcare Ltd. et al.

Represented By

Patent Owner / Respondent

The Johns Hopkins University et al.

Represented By

Tribunal & Venue

Patent Information

Address and Attorney/Agent Information

Power of Attorney & Correspondence

Attorney / Agent Information

Proceeding Documents

Termination Decision: TEMINATION Due to Settlement After Institution of Trial TERMINATE

Joint Motion to Keep Business Confidential and Separate MOTION

Joint Motion to Terminate MOTION

ORDER Setting Oral Argument 37 C.F.R. § 42.70 ORDER

Petitioner's Request for Oral Argument OTHER

Patent Owner's Request for Oral Argument OTHER

Order Granting Petitioner’s Motion to Seal ORDER

Vasdev et al., “Metabolic stability of 6,7-dialkoxy-4-(2-, 3- and 4- [18F]fluoroanilino)quinazolines, potential EGFR imaging probes,” Bioorganic & Medicinal Chemistry, 19:2959–2965 (2011) Exhibit

Biotechne R&D Systems, Recombinant Human Fibroblast Activation Protein a/FAP Catalog Number 3715-SE, https://bio-tehche.com/p/proteins-enzymes/recombinant-human-fap-protein-cf_3715-se#product-specifications Exhibit

Petitioner's Motion to Seal Petitioner's Reply to Patent Owner Response and Exhibits MOTION

Arruebo et al., “Assessment of Evolution of Cancer Treatment Therapies,” Cancers, 3:3279–3330 (2011) Exhibit

FDA and EMA Access Data Exhibit

REDACTED Second Declaration of Dr. Brian Zeglis Exhibit

Dr. VanBrocklin Annotation of XY-FAP-02 Exhibit

REDACTED Petitioner's Reply to Patent Owner Response REPLYTOOPP

Dannoon et al., “Structure—Activity Relationship of 18F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer,” Journal of Medicinal Chemistry, 59:5684–5694 (2016) Exhibit

Baker et al., “Influence of fluorophore and linker composition on the pharmacology of fluorescent adenosine A1 receptor ligands,” British Journal of Pharmacology, 159:772-786 (2010) Exhibit

Petitioner's Updated Exhibit List NOTICE

PCT/US2022/023374 Exhibit

BPS Bioscience Inc., FAP His-Tag Recombinant FAP 80100, https://bpsbioscience.com/fap-his-tag-recombinant-80100 Exhibit

Errata to Declaration of Dr. Henry VanBrocklin Exhibit

PREP Tissue, The Human Protein Atlas, https://www.proteinatlas.org/ENSG00000085377-PREP/tissue Exhibit

Transcript of the Deposition of Dr. Henry VanBrocklin, July, 29, 2026 Exhibit

Second Declaration of Kushan Exhibit

Fulop et al., “Prolyl Oligopeptidase: An Unusual ß-Propeller Domain Regulates Proteolysis,” Cell, 94:161–170 (1998) Exhibit

Su et al., “Evaluation of [18F]getfitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors,” European Journal of Nuclear Medicine and Molecular Imaging, 35:1089–1099 (2008) Exhibit

Huang et al., “The Synthesis and Structural Requirements for Measuring Glucocorticoid Receptor Expression In Vivo with ± 11C-YJH08 PET,” Journal of Nuclear Medicine, 62:(5) 723–731 (2020) Exhibit

Ganguly et al., “A high-affinity [18F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer,” Journal of Nuclear Medicine and Biology, 42:780–787 (2015) Exhibit

Dr. VanBrocklin Annotation of XY-FAP-01 Exhibit

Walsh et al., “Biopharmaceutical benchmarks 2022,” Nature Biotechnology, 40:1722-1760 (2022) Exhibit

Frangioni, “In vivo near-infrared fluorescence imaging,” Current Opinion in Chemical Biology, 7:626–634 (2003) Exhibit

Notice of Joint Stipulation to Modify Due Date 2 NOTICE

Order: REVISED SCHEDULING ORDER ORDER

Exhibit 3004 Exhibit

EX2060 - Teleconference Transcript Exhibit

Patent Owner's Updated Exhibit List NOTICE

Notice of Joint Stipulation to Modify Due Date 2, 3, 5, and 7 NOTICE

Ex. 3003 Exhibit

ORDER Conduct of the Proceeding 37 C.F.R. § 42.5 ORDER

REVISED SCHEDULING ORDER ORDER

Joint Motion to Enter Modified Protective Order MOTION

EX2044 - Jensen Exhibit

EX2028 - Sugiara 2014 Exhibit

EX2026 - US-633 Tethers (Zeglis Annotations) Exhibit

Patent Owner Response RESPONSE

EX2022 - Zeglis Declaration Errata Exhibit

EX2043 - Penner 2012 Exhibit

EX2036 - Rüger 2014 Exhibit

EX2034 - Aertgeerts 2005 Exhibit

EX2038 - Huang 2011 Exhibit

EX2029 - Testa 2000 Exhibit

EX2025 - US-633 Ia-Ik (Zeglis Annotations) Exhibit

EX2035 - Laverman 2015 Exhibit

EX2032 - Scott 2003 Exhibit

EX2023 - Zeglis 2013 II Exhibit

EX2045 - WO2022212958A1 Exhibit

EX2041 - Zeglis 2016 Exhibit

EX2040 - Zeglis 2015 Exhibit

EX2037 - LeBeau 2009 Exhibit

EX2024 - Poplawski 2013 Exhibit

EX2027 - Zeglis Deposition Transcript Exhibit

EX2030 - Siwowska 2017 Exhibit

EX2039 - Keane 2011 Exhibit

EX2046 - Xu Exhibit

EX2031 - Fischer 2012 Exhibit